Correction: Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Correction: Impact of Timing for Adjuvant Chemotherapy Following Cytoreductive Surgery on Survival in Epithelial Ovarian Cancer: A Retrospective Cohort Analysis
Clinical Scorecard: Correction: Impact of Timing for Adjuvant Chemotherapy Following Cytoreductive Surgery on Survival in Epithelial Ovarian Cancer: A Retrospective Cohort Analysis
At a Glance
Category
Detail
Condition
Epithelial Ovarian Cancer
Key Mechanisms
Cytoreductive surgery followed by adjuvant chemotherapy
Target Population
Patients with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Care Setting
Oncology department in a hospital setting
Key Highlights
Retrospective cohort study design
Inclusion of patients treated at Nottingham University Hospitals
Focus on timing of adjuvant chemotherapy after surgery
Study period from January 2016 to December 2021
Cohort consisted of 145 eligible patients
Guideline-Based Recommendations
Diagnosis
Histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Management
Maximal-effort cytoreductive surgery followed by adjuvant platinum-based chemotherapy
Monitoring & Follow-up
Survival outcomes assessed through Kaplan–Meier survival analyses
Risks
Exclusion of patients with recurrent disease or non-epithelial ovarian tumors
Patient & Prescribing Data
145 patients who underwent surgery and chemotherapy
Primary or interval cytoreductive surgery followed by adjuvant chemotherapy
Clinical Best Practices
Ensure accurate patient selection based on histopathology
Adhere to guidelines for timing of adjuvant chemotherapy
